CStone Pharmaceuticals (STU:PH4) Net Interest Margin (Bank Only) %


STU:PH4 CStone Pharmaceuticals STU:PH4
34 GF Score
Price €0.55
GF Value €0.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:PH4
34GF Score
CStone Pharmaceuticals STU:PH4
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CStone Pharmaceuticals (STU:PH4) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of €0.55 is trading 355.2% above its estimated GF Value™ of €0.12. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:PH4:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.12 vs. price of €0.55 (355.2% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the STU:PH4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges CSPHF:USA02616:Hong Kong
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
34GF Score

Get the complete analysis for STU:PH4

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.55
Price
€0.12
GF Value